Thymic stromal lymphopoietin controls hair growth

Shannon, Jessica; Corcoran, David L.; Murray, John; Ziegler, Steven F.; MacLeod, Amanda S.; Zhang, Jennifer

doi:10.1016/j.stemcr.2022.01.017

Cited by 5 publications

(2 citation statements)

References 82 publications

(132 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thymic stromal lymphopoietin, a pleiotropic cytokine encoded by Tslp , has been implicated in the pathogenesis of multiple skin diseases [ 19 ]. However, it has also been involved in initiating collagen synthesis [ 20 ] in wound healing and wound-induced hair regrowth [ 21 ]. Thus, in concert with other genes, significant downregulation of Tslp might contribute to a higher severity of and delayed wound resolution in the poly (I:C)-pre-treated mice.…”

Section: Discussionmentioning

confidence: 99%

STING Agonist-Induced Skin Inflammation Is Exacerbated with Prior Systemic Innate Immune Activation

Pyclik

Durślewicz

Papinska

et al. 2023

IJMS

View full text Add to dashboard Cite

Activation of the Stimulator of Interferon Genes (STING) protein has paradoxical outcomes in skin disease. STING activation exacerbates psoriatic skin disease and delays wound healing in diabetic mice, yet it also facilitates wound healing in normal mice. To address the role of localized STING activation in the skin, mice were injected subcutaneously with a STING agonist, diamidobenzimidazole STING Agonist-1 (diAbZi). The effect of a prior inflammatory stimulus on STING activation was addressed by pre-treating mice intraperitoneally with poly (I:C). The skin at the injection site was evaluated for local inflammation, histopathology, immune cell infiltration, and gene expression. Serum cytokine levels were measured to assess systemic inflammatory responses. Localized diABZI injection induced severe skin inflammation with erythema, scaling, and induration. However, the lesions were self-limiting and resolved within 6 weeks. At the peak of inflammation, the skin showed epidermal thickening, hyperkeratosis, and dermal fibrosis. Neutrophils, CD3 T cells, and F4/80 macrophages were present in the dermis and subcutaneous layers. Gene expression was consistent with increased local interferon and cytokine signaling. Interestingly, the poly (I:C)-pre-treated mice showed higher serum cytokine responses and developed worse inflammation with delayed wound resolution. Our study demonstrates that prior systemic inflammation amplifies STING-mediated inflammatory responses and skin disease.

show abstract

Section: Discussionmentioning

confidence: 99%

STING Agonist-Induced Skin Inflammation Is Exacerbated with Prior Systemic Innate Immune Activation

Pyclik

Durślewicz

Papinska

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…However, the anti-TSLP human monoclonal antibody tezepelumab is modest or nonsignificant compared to placebo in improving pruritic skin lesion in AD, as shown in a randomized phase 2a clinical trial [ 177 , 178 ]. Apart from this, TSLP is also important for promoting wound-induced hair growth and regeneration in mice [ 179 ], which may be an issue that should be considered to use TSLP antagonists for pruritus accompanied by hair loss.…”

Section: Cytokine and Chemotactic Factor Induced Itchmentioning

confidence: 99%

Critical Players and Therapeutic Targets in Chronic Itch

Hua

Chen

Zhu

et al. 2022

IJMS

View full text Add to dashboard Cite

Chronic itch is one of the most prominent clinical characteristics of diverse systematic diseases. It is a devastating sensation in pathological diseases. Despite its importance, there are no FDA-labelled drugs specifically geared toward chronic itch. The associated complex pathogenesis and diverse causes escalate chronic itch to being one of the top challenges in healthcare. Humanized antibodies against IL-13, IL-4, and IL-31 proved effective in treatment of itch-associated atopic dermatitis but remain to be validated in chronic itch. There are still no satisfactory anti-itch therapeutics available toward itch-related neuropeptides including GRP, BNP, SST, CGRP, and SP. The newly identified potential itch targets including OSM, NMB, glutamate, periostin, and Serpin E1 have opened new avenues for therapeutic development. Proof-of-principle studies have been successfully performed on antagonists against these proteins and their receptors in itch treatment in animal models. Their translational interventions in humans need to be evaluated. It is of great importance to summarize and compare the newly emerging knowledge on chronic itch and its pathways to promote the development of novel anti-itch therapeutics. The goal of this review is to analyze the different physiologies and pathophysiologies of itch mediators, whilst assessing their suitability as new targets and discussing future therapeutic development.

show abstract